Detection of Efflux Pump Genes (adeA, adeB, adeC and abeM) in Acinetobacter baumannii Isolated from Hospitalize Patients, North-west of Iran

Authors
1 Department of Microbiology, Shahid Beheshti University, M.C International Branch, Tehran, IR Iran
2 Department of Biotechnology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Shahid Beheshti University. M.C. International Branch, Tehran, IR Iran
4 Department of Microbiology, Imam Reza Hospital, Tabriz, IR Iran
Abstract
Background: The importance of this research was to determine the prevalence of efflux pump genes among Acinetobacter baumannii isolates from hospitalized patients in Imam Reza hospital in Tabriz, Iran.
Materials and Methods: This descriptive study was conducted in the Imam Reza hospital, Tabriz, IR Iran during June 2013 to March 2014. Twenty-six strains were isolated from female patients (42.6%) and thirty-five from male patients (57.4%). Clinical specimens were cultured for isolation of the microbial agents of A. baumannii. The isolated bacteria were identified using biochemical tests. Disk diffusion susceptibility test was used to determine the antimicrobial susceptibility, and E-test methods were also used. The prevalence of efflux pump genes was detected by PCR and sequencing methods.
Results: The resistance of A. baumannii isolates against tested antibiotics was analyzed as follows: 51 (84%) to trimethoprim-sulfamethoxazole, 59 (98%) to ceftazidime, 60 (99%) to ciprofloxacin, 29 (48%) to amikacin, 46 (77%) to gentamicin, 30 (50%) to tobramicin, , 60 (99%) to imipenem,, 60 (99%) to meropenem,, 60 (99%) to ceftriaxon,, 60 (99%) to cefepime,, 60 (99%) to ofloxacin, 6 (11%) to colistin. By using E-test, 45 (73.3%) to imipenem, 57 (93.3%) to ciprofloxacin, 23 (38%) to amikacin were also analyzed. The prevalence of adeA, adeB, adeC, and abeMgenes was 54 (88.5%), 61 (100%), 57 (93.9%), and 60 (98.3%), respectively.
Conclusion: The result of this study showed high incidence of AdeABC efflux pump in MDR A. baumannii isolates and the growing number of nosocomial infections associated with XDR A. baumannii complex, leading to difficulties in antibiotic therapy.

Keywords


  1. Sinha M, Srinivasa H. Mechanism of resistance to crabapenem- resistant Acinetobacter isolates from clinical sample. Ind J MedMicrobiol. 2007; 25(2): 121-5.

  2. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005; 41(6): 848-54.

  3. Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP, Massih RC, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One. 2012; 7(12): e52349.

  4. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs. 2009; 69(12): 1555–1623.

  5. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother. 2001; 45(12): 3375–80.

  6. Coyne S, Rosenfeld N, Lambert T, Courvalin P, Perichon B. Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2010; 54(10): 4389–93.

  7. Damier-Piolle L, Magnet S, Bremont S, Lambert T, Courvalin P. AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother. 2008; 52(2): 557–62.

  8. Coyne S, Courvalin P, Perichon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother. 2011; 55(3): 947–53.

  9. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51(6): 2065–9.

  10. Ruzin A, Immermann FW, Bradford PA. RT-PCR and statistical analyses of adeABC expression in clinical isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex. Microb Drug Resist. 2010; 16(2): 87– 9.

  11. Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother. 2007; 59(5): 1001–4.

  12. Marchand I, Damier-Piolle L, Courvalin P, Lambert T. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumanniiis regulated by the AdeRS two-component system. Antimicrob Agents Chemother. 2004; 48(9): 3298 –3304.

  13. Su XZ, Chen J, Mizushima T, Kuroda T, Tsuchiya T. AbeM, an H+-coupled Acinetobacter baumannii multidrug efflux pump belonging to the MATE family of transporters. Antimicrob Agents Chemother. 2005; 49(10): 4362–4.

  14. Shahcheraghi F, Abbasalipour M, Feizabadi MM, Ebrahimipour GH, Akbari N. “Isolation and genetic characterization of metallo-beta-lactamase and carbapenamase producing strains of Acinetobacter baumannii from patients at Tehran hospitals,” Iran J Microbiol. 2011; 3(2): 68–74.

  15. Clinical and Laboratory Standards Institute (CLSI), “Performance standards for antimicrobial susceptibility testing. Twenty-second informational supplement,” Tech Rep. M100- S22, Fort Wayne, Ind, USA, 2012.

  16. del Mar Tomas M, Cartelle M, Pertega S, Beceiro A, Llinares P, Canle D, et al. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect. 2005; 11(7): 540–6.

  17. Villegas MV, Hartstein AI.  Acinetobacter outbreaks, 1977–2000. Infect Control Hosp Epidemiol. 2003; 24(4): 284–95.

  18. Zhou H, Pi BR, Yang Q, Yu YS, Chen YG, Li LJ, et al. Dissemination of imipenem-resistant Acinetobacter baumannii strains carrying the ISAba1 blaOXA-23 genes in a Chinese hospital. J Med Microbiol. 2007; 56: 1076–80.

  19. Reed MD, Stern RC, O'Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with    cystic fibrosis. J Clin Pharmacol. 2001; 41(6): 645- 54.

  20. Lewis JR, Lewis SA. Colistin interactions with mammalian outothelium. Am J physiol cell physiol. 2004; 286(4): C913-22.

  21. Fallah F, Noori M, Hashemi A, Goudarzi H, Karimi A, Erfanimanesh S, et al. Prevalence of bla NDM, bla PER, bla VEB, bla IMP, and bla VIM genes among Acinetobacter baumannii isolated from two hospitals of Tehran, Iran. Scientifica (Cairo). 2014; 2014: 245162.

  22. Boroumand H, Akhyani 1, Sheikhvatan M. Evaluation of antimicrobial resistance of Acinetobacter baumannii to imipenem, Ciporofloxacin, and Ceftazidime using E-Test. Iran J Public Health.  2009; 38(2): 130-3.

  23. Gholami M, Hashemi A, Hakemi-Vala M, Goudarzi H, Hallajzadeh M. Efflux pump inhibitor phenylalanine-arginine b-naphthylamide effect on the minimum inhibitory concentration of imipenem in Acinetobacter baumannii strains isolated from hospitalized patients in Shahid Motahari burn hospital, Tehran, Iran. Jundishapur J Microbiol. 2015; 8(10): e19048.

  24. Japoni Nejad AR, Sofian M, Ghaznavi-Rad E. Molecular detection of AdeABC efflux pump genes in clinical isolates of Acinetobacter baumannii and their contribution in imipenem resistance. Iran South Med J. 2014; 17(5): 815-23.

  25. Yan Z.-Q, Shen DX, Cao JR, Chen R, Wei X, Lu LP, et al. Susceptibility patterns and molecular epidemiology of multidrug-resistant Acinetobacter baumannii strains from three military hospitals in China. Int J Antimicrob Agents. 2010; 35(3): 269–73.

  26. Lin L, Ling BD, Li XZ. Distribution of the multidrug efflux pump genes, adeABC, adeDE, and adeIJK, and Class 1 integron genes in multiple-antimicrobial-resistant clinical isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex. Int J Antimicrob Agents. 2009; 33(1): 27–32.